Benzinga · Mar 3, 2026
PDS Biotechnology Receives Nasdaq Noncompliance Notice, Gets Time Through Aug. 24 To Regain Compliance
https://www.sec.gov/ix?doc=/Archives/edgar/data/1472091/000114036126007478/ef20067044_8k.htm#fact-identifier-5
PD
NASDAQ · PDSB
PDS Biotechnology Corporation
Healthcare · Biotechnology
$0.75
Up+$0.04 (+6.00%)
Updated Oct 4, 2026, 7:59 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 49.95M
- P/E ratio
- -1.37
- Dividend yield
- 0.00%
- 52-week range
- $0.20 – $1.55
- Volume
- 3.66M
- Avg. volume
- 803.3K
Price performance · PDSB
PDSB price history
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
PDSB closed at $0.75 after 19 trading sessions, up 149.50% for the selected period.
- Last close
- $0.75
- Period change
- +149.50%
- Period low
- $0.29
- Period high
- $0.99
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $0.715 | $0.7502 | $0.709 | $0.7485 | 3.66M |
| Oct 1, 2026 | $0.7499 | $0.76 | $0.7003 | $0.7061 | 3.73M |
| Sep 30, 2026 | $0.7244 | $0.7606 | $0.7101 | $0.7507 | 4.59M |
| Sep 29, 2026 | $0.7506 | $0.77 | $0.7292 | $0.7429 | 2.71M |
| Sep 28, 2026 | $0.7814 | $0.7895 | $0.7283 | $0.7659 | 4.04M |
| Sep 25, 2026 | $0.804 | $0.822 | $0.7805 | $0.7971 | 3.94M |
| Sep 24, 2026 | $0.81 | $0.81 | $0.75 | $0.8001 | 6.1M |
| Sep 23, 2026 | $0.88 | $0.9058 | $0.8177 | $0.8239 | 9.72M |
| Sep 22, 2026 | $0.86 | $0.995 | $0.812 | $0.91 | 24.75M |
| Sep 21, 2026 | $0.9371 | $0.97 | $0.8067 | $0.8419 | 17.07M |
| Sep 18, 2026 | $0.8225 | $0.90 | $0.7512 | $0.8055 | 18.98M |
| Sep 17, 2026 | $0.9077 | $0.9976 | $0.82 | $0.8422 | 35.88M |
| Sep 16, 2026 | $0.649 | $1.06 | $0.62 | $0.9906 | 196.52M |
| Sep 15, 2026 | $0.4916 | $0.7553 | $0.413 | $0.5853 | 372.18M |
| Sep 14, 2026 | $0.2776 | $0.45 | $0.261 | $0.3991 | 80.85M |
| Sep 11, 2026 | $0.32 | $0.32 | $0.293 | $0.2949 | 5.84M |
| Sep 10, 2026 | $0.291 | $0.33 | $0.285 | $0.3153 | 12.73M |
| Sep 9, 2026 | $0.30 | $0.318 | $0.285 | $0.293 | 19.25M |
| Sep 8, 2026 | $0.488 | $0.651 | $0.2565 | $0.30 | 491.12M |
Latest PDSB news
The latest Smart Investors Daily articles mentioning PDSB.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PDSB research
Overview
Company profile and research snapshot.
Company profile
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $9.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 26, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 15, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 25, 2025 | B. Riley Securities | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 20, 2026
PDS Biotechnology Adopts Amended Protocol To Its Phase 3 VERSATILE-003 Clinical Study
PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the adoption of a
Benzinga · Jan 28, 2026
PDS Biotechnology Presents Results Of National Cancer Institute-Led Study Of Investigational Interleukin-12 Tumor Targeted Immunocytokine, PDS01ADC, At AACR Special Conference
NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate CancerPRINCETON, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation
globenewswire.com · Dec 9, 2025
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan
New Patent Grants Broad Composition Claims for PDS0101 Previously Granted Patent Protections and Anticipated Market Exclusivity Provide Protection for PDS0101 in the United States into the 2040s PRINCETON, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Japan Patent Office has issued Patent No.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
